Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Studying Tumor Tissue to Find New Targets in Metastatic Prostate Cancer

Studies tumor tissue from adults with spread prostate cancer to find new drug targets.

Plain-language title generated from the registry record
Registry title: Novel Therapy Target in Metastatic Prostate Cancer

Key facts

Where
Shanghai, ChinaSee the site

Where in China

  • Fudan University Shanghai Cancer CenterShanghai, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Fudan University
Trial code
NCT05577689
Record updated
5 June 2025
Original description
The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.Read full original descriptionShow less

Combining Multi-omics Analysis and Organoid Models to Search for Novel Therapy Target in Metastatic Prostate Cancer

The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.

Inclusion: Histologically confirmed prostate cancer; metastatic disease confirmed by image examination; Patients who can undergo surgery or biopsy for prostate cancer; Able to provide informed consent.

Exclusion: Not accessible to surgery sample; Patients diagnosed with other types of cancer besides prostate cancer; Patients fail to provide informed consent; Other situation that researchers think are unsuitable for this study.

ClinicalTrials.gov NCT05577689